AssetMark Inc
DYN icon

AssetMark Inc’s Dyne Therapeutics DYN Stock Holding History

AssetMark Inc’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$785K Buy
48,702
+20,081
+70% +$461K ﹤0.01% 1146
2026
Q2 		$636K Sell
28,621
-2,441
-8% -$45.4K ﹤0.01% 1178
2026
Q1 		$563K Buy
+31,062
New +$536K ﹤0.01% 1143

Other funds holding DYN

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
CenterBook Partners
CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Arizona State Retirement System
Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return

AssetMark Inc's DYN Position: Q3 2026 in Review

AssetMark Inc increased its Dyne Therapeutics (DYN) stake by 70% in Q3 2026, buying an estimated $461K and bringing the position to 48,702 shares worth $785K. The position accounts for ﹤0.01% of the portfolio, ranked #1146.

AssetMark Inc first reported a position in DYN in Q1 2026 and has held it in 3 quarters since. 61 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • AssetMark Inc held 48,702 shares of Dyne Therapeutics worth $785K as of Q3 2026.
  • AssetMark Inc bought 20,081 Dyne Therapeutics shares in Q3 2026, an estimated $461K.
  • Dyne Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1146 holding.
  • AssetMark Inc first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 61 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.